NCT07479953尚未招募1 期
A Phase I Study of Prenatal Intravenous Gene Transfer With an AAV9 Vector Expressing Human Beta-galactosidase in Type I and Type II GM1 Gangliosidosis
Tippi Mackenzie0 个研究点目标入组 5 人开始时间: 2027年1月1日最近更新:
干预措施
试验速览
- 阶段
- 1 期
- 状态
- 尚未招募
- 发起方
- 入组人数
- 5
- 主要终点
- Safety
研究概览
简要总结
This is a study for the administration of in utero AAV9 transfer in prenatally diagnosed Type I or Type II GM1.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Fetal subject inclusion criteria:
- •3. Live fetuses at 28 0/7 weeks to 35 6/7 weeks gestation
- •Diagnosis of Type I or Type II GM1 in utero by genetic analyses performed on amniotic fluid, fetal blood, placental tissue, or other samples through chorionic villus sampling (CVS), amniocentesis, or cordocentesis.
- •In the event that parents are identified as genetic carriers of Type I or Type II GM1, diagnostic testing for the fetus would be performed to confirm the diagnosis
- •If the fetal genetic testing confirms known mutations, parental genetic testing would not be necessary to enroll the fetus.
- •If one of the mutations is a variant of unknown significance (VUS), but there is a family history (such as a sibling) with confirmed genetic diagnosis and phenotype of disease, this would fulfill the inclusion criteria.
- •The case must be reviewed and accepted by the enrollment advisory board (EAB) based on available clinical data (including age of onset and disease severity of affected family members), clinical presentation, literature review, available case studies, and available research assays (in addition to molecular testing as above).
- •Fetal subject
排除标准
- •1. Fetuses with a concurrent severe structural anomaly, pathogenic genetic diagnosis, or other condition that presents a high risk of fetal mortality.
- •While all possible congenital or structural anomalies that may be exclusionary cannot be listed, the following will be hard exclusions:
- •Cardiac anomaly requiring neonatal surgical intervention
- •Esophageal or bowel atresia
- •Sacrococcygeal teratomas
- •Chromosomal anomalies (e.g. trisomies)
- •Other severe genetic conditions that would impact survival early in life (e.g. muscular dystrophy)
- •Placental malformation that would impact safety of prenatal intervention (e.g. placental accreta)
- •Examples of minor issues that would not be exclusionary include minor genetic or structural anomalies that can be readily treated and would not impact long-term survival, such as:
- •Hearing loss that could be treated with hearing aids
- •Missing digits
- •Hypospadias that can be corrected with a routine postnatal surgery
- •Maternal subject inclusion criteria:
- •Pregnant women age 18 years or older, carrying a live fetus at 28 0/7 weeks to 35 6/7 weeks gestation
- •Identified through the above listed means to be carrying a fetus with GM1 Type I or II
- •Ability to give written informed consent oneself and comply with the requirements of the study
- •5. Maternal anti-AAV9 antibodies <1:
- •Consents to fetal autopsy in the event of fetal demise
- •Maternal subject exclusion criteria:
- •4. Pregnant women with one or more significant comorbidities that would preclude fetal intervention including, but not limited to:
- •inability to complete the procedure secondary to maternal body habitus or placental location
- •significant cardiopulmonary disease
- •mirror syndrome
- •end organ failure
- •altered mental status
- •placental abruption
- •active preterm labor
- •preterm premature rupture of membranes.
- •Pregnant women who require therapeutic dosing of anticoagulation within 24 hours prior to or following the intervention.
- •a. Maternal anti-AAV9 antibodies >1:50
研究组 & 干预措施
Treatment
Experimental
Participants receive investigational product
干预措施: Gene Transfer with an AAV9 Vector Expressing Human ß-galactosidase (Drug)
结局指标
主要结局
Safety
时间窗: 5 years
Safety (maternal and fetal): adverse and serious adverse events including, but not limited to, death within 24 hours after the procedure, stillbirth, death prior to initial hospital discharge, and serious related or serious unexpected adverse events exceeding those expected with the natural history of treated disease during the first five years of life. This will also include pregnancy outcome.
次要结局
- Immunity(5 years)
研究者
Tippi Mackenzie
Professor of Surgery
University of California, San Francisco
相似试验
尚未招募
1 期
AAV2-hAADC for Parkinson's Disease (PDCS-01)NCT07267065Krzysztof Bankiewicz9
终止
1 期
Gene Transfer Clinical Trial for Mucopolysaccharidosis (MPS) IIIBMucopolysaccharidosis Type 3 BNCT03315182Abeona Therapeutics, Inc11
尚未招募
1 期
Prenatal Transplantation for Fetuses With Fanconi AnemiaFanconi AnemiaNCT07408583Agnieszka Czechowicz12
尚未招募
1/2 期
Phase I/II ex vivo gene therapy clinical trial for RDEB using autologous skin equivalent grafts genetically corrected with a COL7A1-encoding SIN retroviral vector2024-518368-10-00Institut National De La Sante Et De La Recherche Medicale3
进行中（未招募）
1 期
Gene transfer clinical trial for Mucopolysaccharidosis IIIAMPS IIIA is a devastating lysosomal storage disease, caused by a N-sulfoglucosamine sulfohydrolase gene defect. Infants with MPS IIIA appear normal at birth, but the disease is relentlessly progressive, with deterioration of social and adaptive abilities, neurocognitive decline, and premature death. Death typically occurs by end of the second or beginning of the third decade. Quite importantly, there is no treatment currently available for the disease.MedDRA version: 20.1 Level: PT Classification code 10056890 Term: Mucopolysaccharidosis III System Organ Class: 10010331 - Congenital, familial and genetic disordersEUCTR2015-003904-21-FRAbeona Therapeutics Inc22